Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nadunolimab (Primary) ; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CESTAFOUR
  • Sponsors Cantargia

    • Most Recent Events

    • 30 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2023 Results from NCT03267316, NCT05116891, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 20 Oct 2022 Planned End Date changed from 6 Sep 2024 to 2 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top